By Kathy Lang, PhD; Jason Shafrin, PhD
PRECISIONheor
What is the right price for a new treatment for COVID-19: ISPOR’s “value flower” or the traditional QALYs approach? Precision’s Jason Shafrin, Kathy Lang and Ross Maclean discuss why the “value flower” model can more accurately value treatments – in cases like COVID-19 – which have a transformational impact on the lives of not only of patients, but also caregivers, employers, and broader society.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
